Based on the measurements of operating efficiency obtained from Cingulate's historical financial statements, Cingulate may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Cingulate's Current Deferred Revenue is most likely to increase significantly in the upcoming years. The Cingulate's current Net Debt is estimated to increase to about 3.7 M, while Short and Long Term Debt Total is projected to decrease to roughly 3 M. Key indicators impacting Cingulate's financial strength include:
Investors should never underestimate Cingulate's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cingulate's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cingulate.
Net Income
(22.24 Million)
Cingulate
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Stock Based Compensation
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Retained Earnings
Inventory
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Cingulate Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cingulate's financial statements are interrelated, with each one affecting the others. For example, an increase in Cingulate's assets may result in an increase in income on the income statement.
Cingulate competes with Senti Biosciences, Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, and Rezolute. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Cingulate's current stock value. Our valuation model uses many indicators to compare Cingulate value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cingulate competition to find correlations between indicators driving Cingulate's intrinsic value. More Info.
Cingulate is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cingulate's Return On Equity is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cingulate by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Cingulate Systematic Risk
Cingulate's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cingulate volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Cingulate correlated with the market. If Beta is less than 0 Cingulate generally moves in the opposite direction as compared to the market. If Cingulate Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cingulate is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cingulate is generally in the same direction as the market. If Beta > 1 Cingulate moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Cingulate Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cingulate's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cingulate growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Cingulate help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cingulate. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cingulate based on widely used predictive technical indicators. In general, we focus on analyzing Cingulate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cingulate's daily price indicators and compare them against related drivers.
When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.